Skip to main content
. 2017 May 11;108(5):1013–1021. doi: 10.1111/cas.13227

Figure 2.

Figure 2

Overall survival. Median overall survival (months) of 24 patients with advanced or relapsed colorectal cancer treated with OCV‐C02 at doses of 0.3, 1, 3, and 6 mg/body. One patient each in cohort 2 (1 mg/body) and cohort 4 (6 mg/body) were treated as censored cases.